Cargando…
Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease
Long-acting muscarinic antagonists (LAMAs), along with long-acting β(2)-agonists (LABAs), are the mainstay for treatment of patients with COPD. Glycopyrrolate, or glycopyrronium bromide, like other LAMAs, inhibits parasympathetic nerve impulses by selectively blocking the binding of acetylcholine to...
Autores principales: | Tashkin, Donald P, Gross, Nicholas J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003532/ https://www.ncbi.nlm.nih.gov/pubmed/29928118 http://dx.doi.org/10.2147/COPD.S162646 |
Ejemplares similares
-
Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy?
por: Tashkin, Donald P, et al.
Publicado: (2018) -
Role of nebulized glycopyrrolate in the treatment of chronic obstructive pulmonary disease
por: Santus, Pierachille, et al.
Publicado: (2017) -
Formoterol for the Treatment of Chronic Obstructive Pulmonary Disease
por: Tashkin, Donald P
Publicado: (2020) -
Impact of baseline clinical features on outcomes of nebulized glycopyrrolate therapy in COPD
por: Tashkin, Donald P., et al.
Publicado: (2021) -
Effect of SGRQ-Defined Chronic Bronchitis at Baseline on Treatment Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate
por: Tashkin, Donald P, et al.
Publicado: (2021)